Biomnis S.A.

What Biomnis S.A. does

Biomnis S.A., operating commercially as Eurofins Biomnis, is a France-headquartered specialized medical biology laboratory and a wholly-owned subsidiary of Eurofins Scientific SE. Founded in 1897 and based in Lyon (with offices in Ivry-sur-Seine/Paris), the company operates a multi-disciplinary diagnostic testing platform organized across 13+ expertise poles including pharmacogenetics, allergology, biochemistry, preventive biology, analytical chemistry, constitutional cytogenetics, prenatal screening (T21, DPNI/NIPT, preeclampsia), genetics, hematology, immunology, infectiology, and solid oncology/malignant hemopathies. The Juvenalis sub-brand extends into consumer-facing preventive and functional biology (nutrition, fertility, healthy aging, stress management). Core proprietary components include the Référentiel des examens reference database, dynamic test protocols, comprehensive allergen IgE coding, clinical pharmacogenetics panels, and the Biomnis Connect digital portal for ordering and results retrieval. With 602 employees in France and an international network of correspondent laboratories including Eurofins Biomnis Ireland & UK, the laboratory processes 39,000+ medical biology examinations per day and delivers 90% of results by the next day.

The business operates a professional-services revenue model, charging testing fees to healthcare professionals, hospitals, clinics, patients, insurance providers, and national health systems rather than disclosing public pricing. Its go-to-market combines direct sales engagement with biologists and prescribers, a content-driven marketing strategy through a medical blog and functional biology webinars, scientific resource distribution (order forms, consent documents, clinical information sheets), and a self-serve online portal (Biomnis Connect). Distribution runs through the in-house France laboratory network with physical collection points, the international correspondent network spanning 43 countries across 3 continents, and direct institutional relationships. As a wholly-owned subsidiary of a publicly-listed laboratory conglomerate, Biomnis S.A. does not raise independent funding, has no public listing, and has no disclosed investor composition.

The customer base is segmented horizontally into two primary groups: healthcare professionals (biologists and prescribers) ordering tests for diagnosis and treatment guidance, and individual patients seeking preventive and wellness testing, particularly through the Juvenalis offering. Pricing is quote-based and negotiated with healthcare institutions and payors rather than publicly listed. The company self-identifies as the European leader in specialized medical biology, with brand heritage and Eurofins-backed regulatory standing across multiple jurisdictions supporting that positioning.

Name

Biomnis S.A.

Legal name

Biomnis S.A.

Website

https://biomnis.com

Company type

Private

Founded year

1897

Operating status

Operating

Short description

Biomnis S.A. (Eurofins Biomnis) is a France-based specialized medical biology laboratory and wholly-owned subsidiary of Eurofins Scientific SE, providing diagnostic testing across 13+ expertise poles to healthcare professionals, hospitals, and patients in 43 countries.

Ownership category

akta.pro rank

Product category

Specialized Medical Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Specialized medical biology
• Clinical diagnostic testing
• Pharmacogenetic testing services
• Prenatal screening laboratory
• Preventive biology assessments

Headquarters

HQ city

Lyon

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Specialized Medical Biology Testing Services: Laboratory testing services for healthcare professionals and patients across multiple specialized disciplines including genetics, oncology, allergology, and pharmacogenetics. Revenue generated through test fees billed to healthcare providers, hospitals, clinics, and patients.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Biomnis S.A. operates as Eurofins Biomnis, a specialized medical biology laboratory providing diagnostic testing services across 13+ expertise poles including pharmacogenetics, allergology, biochemistry, genetics, cytogenetics, hematology, immunology, infectiology, oncology, and prenatal screening (T21, DPNI, pre-eclampsia). The Juvenalis sub-brand extends the offering into preventive and functional biology wellness assessments. Services are delivered through a France-based laboratory network, the Biomnis Connect online portal, and an international correspondent laboratory network spanning 43 countries, processing more than 39,000 specialized medical biology tests per day with 90% of results available the next day.

Product overview

Eurofins Biomnis is a specialized medical biology laboratory operating as part of the Eurofins group, offering a comprehensive portfolio of diagnostic testing services organized across 13 expertise poles. The portfolio centers on specialized medical biology analyses with key areas including pharmacogenetics, prenatal screening (T21/NIPT), genetics, cytogenetics, oncology, and infectious diseases. The company provides access through its Biomnis Connect portal and Référentiel des examens database. The Juvenalis sub-brand extends into preventive and functional biology for wellness-focused consumers. With 602 employees in France processing over 39,000 medical biology tests daily and results available within 24 hours for 90% of tests, the laboratory maintains an international presence across 43 countries on 3 continents.

Differentiator

Problem solved

Functional benefit

Brands

• Juvenalis: Preventive biology brand offering wellness assessments, functional biology, fertility, healthy aging, and stress management services

Products and services

• Pharmacogenetic Clinical Testing (Pharmacogénétique clinique) Clinical pharmacogenetics testing services helping predict individual drug responses based on genetic profiles, particularly relevant for psychiatric medications, antidepressants, and personalized medicine applications. Targeted at prescribing physicians and medical biologists.

Quantifiable outcome

• 90% of test results available the next day
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Eurofins Scientific (Parent Company)coreStrategic or Co-development PartnerEurofins Biomnis operates as a brand and business unit within the Eurofins Scientific group, a global leader in laboratory testing services. The partnership provides access to Eurofins' international network spanning 43 countries, shared technological platforms, and group-wide quality standards and certifications.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Inovie: French regional clinical laboratory network offering routine and specialty testing; competes with Biomnis in France particularly for hospital and prescriber specialty test referrals.
• Synlab: One of Europe's largest medical diagnostics services providers with broad clinical lab and specialty testing operations across multiple countries; competes head-to-head with Biomnis in core European markets on routine and specialty diagnostics.
• Cerba Healthcare: French-headquartered specialty medical biology laboratory group offering a comparable multi-specialty testing menu (genetics, oncology, infectious disease) to hospitals and prescribers across Europe; the closest direct competitor to Biomnis in the French specialty lab market.
• Unilabs: European clinical laboratory and diagnostics provider with extensive specialty testing capacity; directly comparable to Biomnis in offering specialty medical biology services to hospitals, prescribers, and patients across Europe.

Broad incumbents

• Quest Diagnostics: Major US-headquartered diagnostics provider offering advanced genetic, women's health, and specialty testing; comparable to Biomnis in menu breadth and operates globally through affiliates, overlapping with Biomnis in specialty test categories and pharma services.
• Labcorp (Laboratory Corporation of America): Global clinical laboratory leader with a broad diagnostics portfolio including specialty genetic, oncology, and pharmacogenetics testing; competes with Biomnis in cross-border clinical trial central lab and specialty referral work, especially for sponsors seeking EU-based lab capacity.
• Sonic Healthcare: Global medical diagnostics operator with laboratory services across Australia, Europe, and the US; a broader incumbent that overlaps with Biomnis on specialty pathology, genetics, and clinical trial central lab services in European markets.
• Mayo Clinic Laboratories: US-based reference laboratory offering an extensive specialty and esoteric testing menu including genetics and oncology; competes with Biomnis in serving international clients seeking high-complexity specialty tests, including European hospital systems.

Emerging players

• bioMérieux: French-headquartered in vitro diagnostics company with growing specialty testing and infectious disease capabilities; adjacent peer to Biomnis given shared French origin, overlapping infectious disease focus, and expanding menu into specialty diagnostics.

Others

• Eurofins Genoma and Eurofins Clinical Diagnostics (sister Eurofins units): Sister business units within the same Eurofins parent that operate adjacent clinical diagnostics and specialty testing services; technically part of the same group but compete for similar specialty testing contracts and can substitute for Biomnis in tenders and pharma services deals.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/laboratoire-biomnis

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biomnis S.A.